RxDoctor Payments Data

Gary Katzman, MD

Cardiovascular Disease · Providence, RINPI 1003839218

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (51.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Heartflow, Inc. accounts for 68.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $1,401 and has fallen 96.4% since, to $51 in 2025.

$1,711in general payments, 2019–2025

Across 31 payments — averaging $55.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$1K
  • Novartis$245
  • Abbott$159
  • E.r. Squibb & Sons, L.L.C.$36
  • Actelion Pharmaceuticals US, Inc.$34
  • Edwards Lifesciences$21
  • plus $46 from 3 others

What the payments were for

  • Travel & lodging$87651%
  • Food & beverage$81448%
  • Education$211%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,711 in reported general payments places this provider in the 70th percentile of 86 cardiovascular disease providers in Rhode Island.

See all cardiovascular disease providers in Rhode Island

Medicare billing

Part B allowed, 2024
$106,120
Medicare patients
1,489
Services billed
2,852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$145,471
EntrestoSacubitril/Valsartan31$47,415
XareltoRivaroxaban17$17,940
Repatha SureclickEvolocumab23$14,930
JardianceEmpagliflozin12$6,886
Metoprolol Succinate111$2,150
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$1,066
Amiodarone Hcl29$755
Atorvastatin Calcium42$665
Isosorbide Mononitrate ErIsosorbide Mononitrate46$639
Losartan Potassium69$558
Midodrine Hcl14$459
Furosemide44$340
Carvedilol23$287
Lisinopril20$237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$145,471153 claims
NovartisEntresto$245$47,41531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 86 cardiovascular disease providers in Rhode Island.

Other cardiovascular disease in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →